Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + LTT462 combinations in BRAF V600 colorectal cancer
NCT04294160Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of rineterkib in colorectal cancer (CRC) (7 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 30 months, Adverse Events and Serious Adverse Events at 34 months and 3 more. Started Jul 2020; status: terminated.
02
Drugs
rineterkib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04294160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294160.